Immunogenicity and Safety of a Booster Dose of Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 365-569 Days Old Healthy Infants

A Phase III Observer Blind Single-Coordinating Center Pediatric Study in China Comparing a Booster Dose of Vaxem™ Hib to HIBERIX® When Given as Part of a Local Dosing Regimen in Infants

This study will evaluate the safety and immunogenicity of booster dose of two commercially available vaccines used to prevent Haemophilus influenzae type b infections in children 365-569 days of age

Inclusion Criteria:

• Infants 365-569 days of age.

Exclusion Criteria:

• Subjects who already received a booster dose of Hib vaccine.
• History of serious reaction(s) following vaccination.
• Any vaccination within 7 days of study vaccination.
• Known or suspected immune impairment.